|
| 骨质疏松的药物治疗新进展 |
| New progress in drug therapy for osteoporosis |
| |
| DOI：10.3969/j.issn.1006-7108.2012.06.022 |
| 中文关键词: 骨质疏松 药物 治疗 |
| 英文关键词:Osteoporosis Medicine Treatment |
| 基金项目: |
|
| 摘要点击次数: 1270 |
| 全文下载次数: 1683 |
| 中文摘要: |
| 骨质疏松是一种常见的以骨量减少伴有骨组织微结构的破损所致骨脆性骨折危险性增高的全身性代谢性骨病。随着人口老龄化的加大，骨质疏松（特别是绝经后骨质疏松）的相关治疗和及其对社会经济学的影响，将进一步加大。随着对破骨细胞促进骨吸收和成骨细胞促进骨形成的及其它们之间的分子间信号传递的骨生物学详尽的认识，一些新的治疗方法逐渐得到了人们的认可。新的治疗策略旨在抑制骨的吸收，而增加骨的形成。目前最有前途的新的治疗方法包括：地舒单抗，是一种特异性靶向核因子κB 受体活化因子配体( RANKL) 的单克隆抗体；奥达卡替，一种破骨细胞组织蛋白酶K抑制剂；沙拉替尼，一种Src激酶抑制剂；巴多昔芬，一种选择性雌激素调节剂。本综述对这些新的治疗方法逐一进行了讨论，并阐述了其内在的生理学机制。 |
| 英文摘要: |
| Osteoporosis (OP) is a common bone disease characterized by a systemic impairment of bone mass and microarchitecture which results in fragility fractures. With the increasing aged population, the treatment and socio-economic effect on osteoporosis, especially on postmenopausal osteoporosis, will further increase. A sufficient understanding of bone biology with molecules signaling to the communication between bone-resorbing osteoclasts and bone-forming osteoblasts and the orchestrating signaling network has led to gradually recognized novel therapeutic targets by the people. The new treatment strategy has been designed that aims to inhibit excessive bone resorption and to increase bone formation. The most promising novel treatments include: Denosumab, a monoclonal antibody against receptor activator of NF-κB ligand; Odanacatib, a specific inhibitor of osteoclast protease cathepsin K; Saracatinib, a Src kinase inhibitor; and a selective estrogen receptor modulator (SERM), Bazedoxifene. This review discusses these new therapies and explains their internal physiological mechanisms. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |